頭頸部癌に対する分子標的薬治療：EGFR SignalingとCrosstalk

• 馬場 優

  那須赤十字病院耳鼻咽喉科

書誌事項

タイトル別名

• Molecular Targeting Drugs for Head and Neck Cancer: EGFR Signaling and its Crosstalk
• アタマ ケイブガン ニ タイスル ブンシ ヒョウテキヤク チリョウ:EGFR Signaling ト Crosstalk

抄録

Molecular targeting drugs (MTG) have proved effective for head and neck cancer (HNC) not only in basic studies but in many clinical trials. Cetuximab, an anti-EGFR monoclonal antibody, is a key drug for regimens including MTG. However, monotherapy with cetuximab has shown limited success. Molecular crosstalk has been observed between EGFR and IGF1R signaling through the PI3kinase/Akt pathway, as has molecular crosstalk between the NFkappaB and STAT3 signaling pathways. Therefore, the combination of cetuximab with an agent that inhibits the activation of both Akt and STAT3 may overcome resistance to cetuximab in HNC.<br>

収録刊行物

• 耳鼻咽喉科臨床

  耳鼻咽喉科臨床 106 (1), 89-93, 2013

  耳鼻咽喉科臨床学会

キーワード

• head and neck cancer
• crosstalk
• cetuximab
• resistance

詳細情報

• CRID: 1390001204270541184
• NII論文ID: 10031141243
• NII書誌ID: AN00107089
• DOI: 10.5631/jibirin.106.89
• ISSN: 18844545
• ISSN: 00326313
• NDL書誌ID: 024210076
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I024210076
• Web Site: https://search.jamas.or.jp/link/ui/2013105284
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可